Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery View more
Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries View more
Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer View more